{"nctId":"NCT01044459","briefTitle":"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","startDateStruct":{"date":"2009-11"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":605,"armGroups":[{"label":"Aclidinium Bromide 200 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium Bromide 200 µg"]},{"label":"Aclidinium Bromide 400 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium Bromide 400 µg"]}],"interventions":[{"name":"Aclidinium Bromide 200 µg","otherNames":[]},{"name":"Aclidinium Bromide 400 µg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2010; postbronchodilator FEV1/FVC \\< 70%, and postbronchodilator FEV1 ≥ 30% and \\< 80% predicted\n* Current or former cigarette smokers\n\nExclusion Criteria:\n\n* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit\n* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1\n* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness\n* History or presence of asthma verified from medical records\n* Chronic use of oxygen therapy greater than or equal to 15 hours per day\n* Patient with uncontrolled infection due to HIV and/or active hepatitis\n* Patients with a history of hypersensitivity reaction to inhaled anticholinergics\n* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)","description":"Change From Baseline in Morning Predose (Trough) FEV1 in liters at Week 52.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.034","spread":"0.015"},{"groupId":"OG001","value":"0.072","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak FEV1","description":"Change From Baseline in Peak FEV1 in liters at Week 52.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.185","spread":"0.015"},{"groupId":"OG001","value":"0.214","spread":"0.015"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":311},"commonTop":["Chronic Obstructive Pulmonary Disease"]}}}